Press Release:
Without directly invading the brain or nerves, the virus responsible for COVID-19 causes potentially damaging neurological injuries in about one in seven infected, a new study shows. These injuries range from temporary confusion due to low body-oxygen levels, to stroke and seizures in the most serious cases, say the study authors.
Led by researchers at NYU Grossman School of Medicine, the study showed no cases of brain or nerve inflammation (meningitis or encephalitis), indicating no immediate invasion of these organs by the pandemic virus, SARS-CoV-2.
While this should reassure patients, the neurological complications of COVID-19 should be taken seriously because they dramatically raise a patient’s risk of dying while still in hospital (by 38 percent), researchers say. Such adverse effects also raise a coronavirus patient’s likelihood (by 28 percent) of needing long-term or rehabilitation therapy immediately after their stay in hospital.
“The results of our study showed no signs that the coronavirus directly attacks the nervous system,” says study lead investigator Jennifer Frontera, MD. “The neurological complications seen in COVID-19 are predominately the secondary effects of being severely ill and suffering from low oxygen levels in the body for prolonged periods of time,” says Frontera, a professor in the Department of Neurology at NYU Langone Health.
Published in the journal Neurology online Oct. 5, the study closely monitored the progress of 606 COVID-19 adult patients diagnosed with brain or other nerve-related medical conditions at any of four NYU Langone hospitals in New York City and Long Island between March 10 and May 20, when coronavirus infections were at their peak in the region.
Frontera says that ahead of the pandemic, dozens of NYU Langone neurologists and trainees had deployed across its medical centers to assist with the expectant surge of COVID-19 patients.
Early reports from Asia and Europe, where infections had spiked before rising in the United States, she says, had also “raised the alarm” about possible brain damage from coronavirus infection. Because of this, the research team was ready to look for any signs of neurological dysfunction among the thousands of patients being admitted to hospital in the spring. Among all the hospitals, 4,491 patients tested positive for COVID-19 during that time.
Among the study’s other key results was that common neurological problems, such as confusion caused by chemical electrolyte imbalances, severe infection or kidney failure, usually arose within 48 hours of developing general COVID-19 symptoms, including fever, difficulty breathing, and cough.
Half of those neurologically affected were over the age of 71, which researchers say is significantly older than the other 3,885 patients with COVID-19 (at a media age of 63) who did not experience brain dysfunction. Most were men (66 percent) and white (63 percent). Frontera notes that the study results do suggest that Blacks are not at greater risk of neurological complications than other COVID-19 patients, which is “welcome news,” given that Blacks are widely known to be at greater risk of death from coronavirus infection. However, she says this potentially important observation requires further investigation.
While the coronavirus is known to attack other organs, including blood vessels and the heart, researchers say its main target is the lungs, where it makes breathing difficult, starving the body of oxygen it needs to stay alive. Low levels of oxygen in the body and brain was another common neurological problem, study results showed, that could lead to confusion, coma, or permanent brain damage.
“Our study results suggest that physicians need to be more aggressive in stabilizing body oxygen levels in patients with COVID-19 as a potentially key therapy for stopping, preventing and/or possibly reversing neurological problems,” says study senior investigator Steven Galetta, MD.
###
Galetta, the Philip K. Moskowitz, MD Professor and chair of the Department of Neurology at NYU Langone, says various blood-oxygen-raising therapies that could possibly work against neurological problems in patients with COVID-19 include early intubation or use of heart-lung machines, called ECMO, which mechanically “clean” the blood and “deliver” oxygen into it.
Funding support for the study was provided by National Institutes of Health grant P30 AG066512 and NYU Langone.
Advertisement:
- Expiration Date Extension: On July 8, 2022, the FDA granted another three-month shelf-life extension for the iHealth COVID-19 Antigen Rapid Test, which extended the shelf-life of all iHealth tests from 6 months to 12 months. Please refer to the FDA website for the detailed list of extended expiration dates by lot numbers: https://www.fda.gov/media/158007/download
- FDA Authorized 15-Minute Self-Test: The test is a 15-minute self-test to detect whether or not an individual has COVID-19. The test can be completed in the comfort of your own home without the need to ship your sample to a lab.
- Easy to Use with Zero Discomfort: The test can be done by inserting 1/2 to 3/4 inch of a simple non-invasive nasal swab. Step-by-step instructional videos are available in our app (Installation of the app is optional).
- For Ages 2 and Above: The self-administered test is recommended for individuals aged 15 years and older. Adult-collection is required for testing children 2-14 years old.
- Manage Group Testing Via Mobile App: The iHealth Test app allows the administrator of a small group to monitor and track the group members’ test results as needed at school, work, or an event.
- Expiration Date Extension: On July 8, 2022, the FDA granted another three-month shelf-life extension for the iHealth COVID-19 Antigen Rapid Test, which extended the shelf-life of all iHealth tests from 6 months to 12 months. Please refer to the FDA website for the detailed list of extended expiration dates by lot numbers: https://www.fda.gov/media/158007/download
- FDA Authorized 15-Minute Self-Test: The test is a 15-minute self-test to detect whether or not an individual has COVID-19. The test can be completed in the comfort of your own home without the need to ship your sample to a lab.
- Easy to Use with Zero Discomfort: Test can be done by inserting 1/2 to 3/4 inch of a simple non-invasive nasal swab. Step-by-step instructional videos are available in our app (Installation of app is optional).
- For Ages 2 and Above : The self-administered test is recommended for individuals aged 15 years and older. Adult-collection is required for testing children 2-14 years old.
- Manage Group Testing Via Mobile App: The iHealth Test app allows the administrator of a small group to monitor and track the group members’ test results as needed at school, work or an event.
- FDA EUA Authorized OTC at-Home Rapid Antigen Self-Test Kit: The CLINITEST Rapid COVID-19 Antigen Self-Test is intended to aid in the rapid detection of SARS-CoV-2 (the virus that causes COVID-19) and provides accurate results in just 15 minutes. Eligible for reimbursement through select insurance providers.
- Easy-to-use, Easy-to-read: No special training or equipment required. All it takes is a quick and gentle nasal swab to collect the sample, drop onto the visually-read test cassette, and interpret the results. Step-by-step instructional video is available online, along with downloadable Instructions for Use (IFU).
- Accurate Results for Peace of Mind: Get the answers you need with a fast, reliable, and convenient at-home OTC COVID-19 self-test. Authorized for unsupervised self-testing use by individuals aged 14 and older (or adult-collected samples from individuals ages 2-13). Innovation you can trust, from a brand already relied on globally to support the world’s toughest health challenges.
- Committed to Quality: Siemens Healthineers has conducted internal assessments to confirm that the CLINITEST Rapid COVID-19 Antigen Self-Test is able to detect all current Variants of Concern, including Delta and Omicron variants.
- Amazon Kindle Edition
- Schwab, Klaus (Author)
- English (Publication Language)
- 282 Pages - 07/13/2020 (Publication Date) - Forum Publishing (Publisher)
- SHELF-LIFE EXTENSION: Our tests sold from Amazon has 6 months longer shelf-life than the printed expiration date on the package. FDA granted 6 months shelf-life extension for the Celltrion DiaTrust COVID-19 Ag Home Test, which extended the shelf life from 12 months to 18 months as of May 20th, 2022. The affected lot numbers can be found on FDA’s website: https://www.fda.gov/media/159236/download
- FDA EUA-AUTHORIZED HOME TEST (OTC): Celltrion DiaTrust COVID-19 Ag Home Test is an FDA EUA-authorized COVID-19 rapid antigen at-home testing kit. Self-test in the comfort of your own home, and get the relief you need, fast. For use in individuals aged 14 years and older.
- TWO TESTS PER KIT: Each kit contains supplies for two tests: swabs, test devices, test tubes (extraction buffer), filter caps, and an Instructions for Use manual. Test tubes and filter caps for two tests are enclosed in one inner package.
- RAPID RESULTS AND PERCENTAGE: The test gives you results in just 15 minutes and is authorized for at-home use without submitting sample collection to labs. Our home test is capable of detecting COVID-19 with 99.8% Negative Percent Agreement and 86.7% Positive Percent Agreement.
- SIMPLE STEPS: Just four steps from start to finish. The DiaTrust system makes getting your results easy. Detailed instruction is enclosed with the product and video instruction is available on both our product page and website. Test yourself and a family member at the same time or take two tests in a designated timeframe for travel, work, and more.
- Coleman, Vernon (Author)
- English (Publication Language)
- 512 Pages - 07/07/2022 (Publication Date) - Korsgaard Publishing (Publisher)
- Amazon Prime Video (Video on Demand)
- Timothy Sly, Donald J. Trump, Xi Jinping (Actors)
- Connor Luke Simpson (Director) - Sam Tilston (Producer)
- English (Playback Language)
- English (Subtitle)
I get commissions for purchases made through links on this website. As an Amazon Associate I earn from qualifying purchases.